Roth Capital Has Pessimistic Outlook of ZVRA FY2029 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Roth Capital dropped their FY2029 earnings estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.05 for the year, down from their previous forecast of $2.26. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

ZVRA has been the topic of a number of other research reports. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Guggenheim set a $21.00 price target on shares of Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $21.71.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $7.92 on Thursday. The company’s fifty day moving average price is $7.95 and its 200 day moving average price is $8.14. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The stock has a market capitalization of $422.74 million, a P/E ratio of -4.02 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Insider Transactions at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics in the fourth quarter valued at approximately $94,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $94,000. Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after acquiring an additional 4,384 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.